Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived stromal vascular fraction (25f851)
- Development stage
- Unknown
- Lead developer
- Robert W. Alexander
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous adipose-derived stromal vascular fraction (AD-cSVF) is a cellular therapy composed of a heterogeneous population of cells, including mesenchymal stem cells (MSCs), endothelial progenitor cells, and immune cells, isolated from a patient's own adipose tissue. Developed by Robert W. Alexander, MD, FICS, for the treatment of benign prostatic hyperplasia (BPH), the therapy is prepared using a closed system (such as the Centricyte 1000) to enzymatically release and concentrate cells from the adipose matrix. When administered intravenously, AD-cSVF is thought to exert systemic anti-inflammatory and immunomodulatory effects that reduce prostatic inflammation and hypertrophy, thereby improving urinary tract symptoms like nocturia, urgency, and incomplete bladder emptying.
- Other names
- autologous adipose-derived stem cellsadipose-derived stromal vascular fractionAD-tSVF
Beyond the preview
Go deeper on autologous adipose-derived stromal vascular fraction (25f851).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived stromal vascular fraction (25f851).